DCTH (Delcath Systems) Short Interest


DCTH Delcath Systems Inc DCTH
70 GF Score
Price $12.23
GF Value $36.67
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Delcath Systems Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

DCTH vs OFIX, VMD, CLPT: Short Interest Comparison

For the Medical Devices subindustry, Delcath Systems's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delcath Systems Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Short Interest distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Short Interest falls into.


DCTH
70GF Score
Delcath Systems Inc DCTH
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $12.23 is trading 66.6% below its estimated GF Value™ of $36.67. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • Short Interest:
  • GF Value™: $36.67 vs. price of $12.23 (66.6% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score

Get the complete analysis for DCTH

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.23
Price
$36.67
GF Value